Rectal Cancer

Expert care for rectal cancer with neoadjuvant chemoradiation, surgery (including sphincter-preserving techniques), and adjuvant therapy.

Back to All Treatments
Rectal Cancer

Rectal Cancer

Solid Tumors

Overview

Expert care for rectal cancer with neoadjuvant chemoradiation, surgery (including sphincter-preserving techniques), and adjuvant therapy.

When to Consult

After colonoscopy findings, rectal bleeding, or confirmed rectal cancer diagnosis.

What to Bring

Colonoscopy reports, biopsy results, MRI pelvis, CT scans, CEA blood test results, and surgical history.

Risk Factors

Age (more common after 50)
Family history of colorectal cancer
Personal history of polyps or colorectal cancer
Inflammatory bowel disease (IBD)
Genetic syndromes (Lynch syndrome, FAP)
Diet high in red/processed meat
Radiation therapy to pelvis
Obesity and sedentary lifestyle

Causes

Genetic mutations in rectal cells
Adenomatous polyps progression
Inflammatory bowel disease
Dietary factors
Genetic predisposition
Chronic inflammation
Radiation exposure
Complex genetic and lifestyle factors

Treatment Options

Neoadjuvant Chemoradiation

Pre-surgical treatment combining chemotherapy (5-FU or capecitabine) with radiation therapy to shrink tumors, improve surgical outcomes, and increase chances of sphincter-preserving surgery. Standard approach for locally advanced rectal cancer.

Surgery

Surgical options include low anterior resection (LAR) with sphincter preservation, abdominoperineal resection (APR) with permanent colostomy, or transanal endoscopic microsurgery (TEM) for early-stage tumors. Total mesorectal excision (TME) technique ensures complete tumor removal.

Adjuvant Chemotherapy

Post-surgical chemotherapy using FOLFOX or capecitabine regimens to eliminate remaining cancer cells and reduce recurrence risk. Typically administered after neoadjuvant therapy and surgery for stage II/III rectal cancer.

Targeted Therapy

Precision treatments including anti-angiogenic agents (bevacizumab) and EGFR inhibitors (cetuximab, panitumumab) for KRAS wild-type advanced rectal cancer. Based on molecular profiling and genetic mutations.

Immunotherapy

Immune checkpoint inhibitors (pembrolizumab, nivolumab) for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) rectal cancers. Particularly effective in advanced or recurrent disease with these genetic features.

Watch-and-Wait Approach

For selected patients with complete clinical response after neoadjuvant chemoradiation, close monitoring without immediate surgery may be considered, preserving organ function while maintaining careful surveillance.

Need Treatment?

Schedule a consultation to discuss treatment options for Rectal Cancer.